We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

NIH and FDA Announce Release of Draft Clinical Trial Protocol Template; Call for Comments by April 17, 2016

Katelyn (Katie) A. Ruiz

Katelyn (Katie) A. Ruiz,

Washington, D.C.

Michael N. Druckman

Michael N. Druckman,

Washington, D.C.

Robert F. Church

Robert F. Church,

Los Angeles

William (Bill) F. Ferreira

William (Bill) F. Ferreira,

Washington, D.C.

28 March 2016
The National Institutes of Health (NIH) and Food and Drug Administration (FDA) announced on March 17, 2016, their co-development of a draft clinical trial protocol template for use by NIH-funded investigators.  The template is meant for use in writing phase 2 or 3 clinical trial protocols where Investigational New Drug application (IND) or Investigational Device Exemption (IDE) applications are required.

The template provides instructions and sample text that are intended to facilitate the preparation of consistent, organized, and complete protocols, so that clinical trials can be properly and more efficiently reviewed by the agencies.  The template protocol follows the International Conference on Harmonisation E6 Good Clinical Practice guidance.

NIH and FDA request public comment on the draft template from investigators, investigator-sponsors, institutional review board members, and any other stakeholders involved in protocol development and review.  The agencies are particularly interested in the utility of the template and the readability and clarity of the instructional and sample text.  Comments will be accepted through April 17, 2016, but the announcement notes that comments will be used at the agencies’ discretion and responses to comments will not be provided.  Draft template documents can be found here, and responses may be made here.

If you have any questions about the request for public comment from the NIH and FDA, please feel free to contact one of the Hogan Lovells authors of this blog post.

Katelyn (Katie) A. Ruiz

Katelyn (Katie) A. Ruiz,

Washington, D.C.

Michael N. Druckman

Michael N. Druckman,

Washington, D.C.

Robert F. Church

Robert F. Church,

Los Angeles

William (Bill) F. Ferreira

William (Bill) F. Ferreira,

Washington, D.C.

Loading data